Drug Trial Radar · NCT07931573
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,200
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Jul 4, 2028
Study completion Aug 8, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will get one of the following: Zenagamtide (the treatment being tested) or Semaglutide (an approved and commonly prescribed treatment used as comparator).
Conditions
- Type 2 Diabetes
Interventions
ZenagamtideDrug
Zenagamtide will be administered subcutaneously
SemaglutideDrug
Semaglutide will be administered subcutaneously
PlaceboDrug
Placebo matched to semaglutide or zenagamtide will be administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in glycated haemoglobin (HbA1c) [non-inferiority]Time frame: From baseline (week 0) to week 60
Locations
230 sites in 22 countries. Site status is shown where the registry gives one.
Rio Clinical Trials Arizona
Phoenix, Arizona
Scripps Whittier Diabetes Inst
La Jolla, California
Diabetes & Endocrine Specialists - La Mesa
La Mesa, California
First Valley Med Grp Lancaster
Lancaster, California
Los Angeles Institute for Metabolic Research
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Oasis Hlthcr Med Group
Palm Springs, California
Linda Vista Health Care Ctr
San Diego, California
Southern Cal Clinical Research
Santa Ana, California
Encompass Clinical Research_Spring Valley
Spring Valley, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Chase Medical Research LLC
Waterbury, Connecticut
Encore Medical Research LLC
Hollywood, Florida
University of Florida Cardiology
Jacksonville, Florida
My Preferred Research
Miami, Florida
New Horizon Research Center
Miami, Florida
GTL Med & Res Group
Miami, Florida
Life Medical Research Group
Miami Gardens, Florida
South Broward Research LLC
Miramar, Florida
Adult Medicine of Lake County, Inc
Mt. Dora, Florida
West Orange Endocrinology
Ocoee, Florida
Florida Institute for Clinical research
Orlando, Florida
True Blue Clinical Research
Tampa, Florida
Encore Medical Research of Weston
Weston, Florida
Solaris Clinical Research
Meridian, Idaho
Clinical Invest Special_Gurnee
Gurnee, Illinois
Cotton O'Neil Diab & Endo Ctr
Topeka, Kansas
MedStar Health Research Institute
Olney, Maryland
Endo And Metab Cons
Rockville, Maryland
Brigham & Women's Hospital
Boston, Massachusetts
Elite Clinical Research
Flint, Michigan
StudyMetrix Research LLC
City of Saint Peters, Missouri
Palm Research Center Inc-Vegas
Las Vegas, Nevada
Southern NH Diabetes and Endo_Nashua
Nashua, New Hampshire
AMC Community Endocrinology
Albany, New York
Southgate Medical Group, LLP
West Seneca, New York
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Monroe Biomedical Research, LLC
Monroe, North Carolina
Accellacare
Wilmington, North Carolina
Diab & Endo Assoc of Stark Co
Canton, Ohio
Showing 40 of 230 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.